Myricetin derivative-rich fraction from prevents high-fat diet-induced obesity, glucose intolerance and oxidative stress in C57BL/6J mice.

Aim: A high-fat diet (HFD) can lead to obesity and related metabolic disorders. This study evaluated the preventive efficacy of myricetin derivative-rich fraction (MD) from leaf extract against HFD-induced obesity, hyperglycaemia, and oxidative stress in C57BL/6J mice.

Methods: HFD-fed mice were administered MD (50 mg/kg, 100 mg/kg, and 150 mg/kg) or 2 mg/kg metformin (positive control) orally for 16 weeks. Normal diet and HFD-fed control groups received normal saline.

Results: MD dose of 50 mg/kg was better than 100 mg/kg and 150 mg/kg in significantly reducing weight-gain, glucose intolerance, insulin resistance, lipid accumulation in liver and kidney, and improving the serum lipid profile. Lowered protein carbonyls and lipid hydroperoxides in urine and tissue homogenates and elevated reduced glutathione, ferric reducing antioxidant power (FRAP), and Trolox equivalent antioxidant capacity (TEAC) levels in tissue homogenates indicated amelioration of oxidative stress.

Conclusion: MD has therapeutic value in the prevention and management of obesity, hyperglycaemia, and oxidative stress.